Botulinum toxin therapy for palmar hyperhidrosis: experience in an Iranian population.

There seems to be a genetic predisposition to primary (essential) hyperhidrosis and it often manifests itself in childhood or puberty. Essential or focal hyperhidrosis characteristically does not occur during sleep, but is made worse by heat and emotional situations, as it is considered that the hypothalamic sweat centers are more sensitive to emotional stimuli in nonhyperhidrotic subjects. 2 However, it is estimated that 0.6–1.0% of the population suffers from primary (essential) hyperhidrosis and in many it can become chronic and can lead to significant disruption in both social and professional life, leading to a marked impact on the patient's quality of life (QoL). 2 Patients find the symptoms embarrassing and often complain that the anticipation of sweating leads to avoidance of certain activities. 3 Sweat rates are highly variable between individuals and are thought to be a factor of acclimatization, sex, age, and possibly diet. 4 The aim of the present study was to evaluate the effectiveness, safety, and adverse reactions of botulinum toxin type A, Dysport® (Speywood Pharmaceuticals, Berkshire, UK) on the patients with recalcitrant palmar hyperhidrosis.